New drug CC312 tested for tough autoimmune cases
NCT ID NCT07193810
First seen Oct 31, 2025 · Last updated May 12, 2026 · Updated 23 times
Summary
This early study is testing the safety of a new drug, CC312, in 6 adults with lupus, myositis, or systemic sclerosis that has come back or not responded to standard treatments. Participants receive increasing doses of CC312 by IV to see if it is safe and tolerable. The goal is to gather initial information on side effects and how the drug works in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Deyang People's Hospital
RECRUITINGDeyang, Sichuan, 618000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.